J&J Launches Largest Coronavirus Vaccine Study

“Our Phase 3 program is intended to be as robust as possible, could include up to 60,000 participants and will be conducted in places with high incidence rates,” J&J spokesman Jake Sargent said in a statement to CNBC on August 20, 2020. J&J and Janssen Vaccines registered their experimental coronavirus vaccine candidate Ad26.COV2.S for up to 60,000 clinical trial participants in various countries on August 10th.